港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

618.706

+13.1722.18%

涨家数：23

跌家数：8

平家数：3

市盈率：- -

高：627.633

开：605.584

低：600.085

收：605.533

成交量：1.29亿

成交额：38.26亿

市值：3,831.01亿

流通市值：3,410.50亿

数据加载中...

启明医疗-B完成三尖瓣置换CE注册研究的目标试验入组

科技承压下的资金新选择，创新药开启上涨新周期?

创新药如何从工厂直达患者？信达与京东健康打通体重管理“最后一公里”

11月，新主线——极简投研

中国人的药，治世界的病

速递丨10余款癌症管线正在临床推进，和誉医药展示创新管线布局与前沿临床进展

新桥生物携25名全职员工闯关港交所，云顶新耀、康桥资本参股

28家药企涉商业贿赂案！多起医药虚假宣传曝光，大联盟集采中选结果出炉，恒瑞、乐普大爆发

格隆汇港股回购榜 | 10月31日

中国首个，获批上市！

直击国谈第二日：肿瘤、慢病领域重磅药开谈！

猛犸资本局

腾盛博药-B(02137)授出60万份购股权

新股消息 | 礼邦医药递表港交所核心产品AP301已完成中国III期注册临床试验

智通港股解盘 | 月底魔咒再起恒指跌破关口医药目录谈判引发资金涌入

ETF日报：各方面利好消息不断出现，为行业乐观情绪再添一把火，关注创新药板块

创新药突然爆发，基金经理火线解读！多头猛攻，港股通创新药ETF（520880）大阳线拔地而起，放量摸高5.25%！

归创通桥(02190)10月31日耗资约118.74万港元回购5万股

迈博药业-B(02181)：张雁云已获指定为首席独立非执行董事

歌礼制药-B(01672)10月31日耗资约193.27万港元回购20万股

9个月干了过去3年IPO总和，这个领域何以爆发？

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":618.7055,"timestamp":1761898110601,"preClose":605.53326,"halted":0,"volume":128593457,"delay":0,"changeRate":0.021753,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":13.172241,"latestTime":"10-31 16:00:00","open":605.58374,"high":627.6333,"low":600.08484,"amount":3826218301,"amplitude":0.045495,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1762133400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1761874200000,1761883200000],[1761886800000,1761897600000]],"pbRate":5.343409,"peRate":-44.036334,"turnoverRate":0.004666,"increases":23,"decrements":9,"flats":1,"marketCap":383100705664,"floatMarketCap":341050329040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":627.6333,"amplitude":0.045495,"preClose":605.53326,"low":600.08484,"pbRate":"5.343409","latestPrice":618.7055,"volume":128593457,"delay":0,"open":605.58374,"prevYearClose":331.1933,"prevWeekClose":617.318,"prevMonthClose":618.706,"prevQuarterClose":752.859,"fiveDayClose":615.593,"twentyDayClose":752.859,"sixtyDayClose":779.344,"secType":"PLATE","market":"HK","turnoverRate":0.004666,"peRate":-44.036334,"marketCap":383100705664,"floatMarketCap":341050329040,"timestamp":1761898110601,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":23,"down":8,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1110928866","title":"启明医疗-B完成三尖瓣置换CE注册研究的目标试验入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1110928866","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110928866?lang=zh_cn&edition=fundamental","pubTime":"2025-11-02 04:20","pubTimestamp":1762028416,"startTime":"0","endTime":"0","summary":"启明医疗-B完成三尖瓣置换CE注册研究的目标试验入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02500","BK1583","BK1100","BK1574"],"gpt_icon":0},{"id":"2580426810","title":"科技承压下的资金新选择，创新药开启上涨新周期?","url":"https://stock-news.laohu8.com/highlight/detail?id=2580426810","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580426810?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 18:48","pubTimestamp":1761994083,"startTime":"0","endTime":"0","summary":"挖掘潜在投资机会","market":"sg","thumbnail":"https://img3.gelonghui.com/5a971-c08ca7fa-82b4-40e9-9b71-78051864954d.jpg?guru_height=2595&guru_width=4630&guru_size=776778","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/5a971-c08ca7fa-82b4-40e9-9b71-78051864954d.jpg?guru_height=2595&guru_width=4630&guru_size=776778"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3114521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2580995425","title":"创新药如何从工厂直达患者？信达与京东健康打通体重管理“最后一公里”","url":"https://stock-news.laohu8.com/highlight/detail?id=2580995425","media":"北京商报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580995425?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 18:20","pubTimestamp":1761992410,"startTime":"0","endTime":"0","summary":"今年7月，京东健康与信达生物正式签署战略合作协议，两大行业领军企业的联手引发市场广泛关注。近日，京东健康组织媒体团实地探访信达生物苏州工厂与京东物流昆山药品仓，首次向外界全面展示了双方在体重管理领域的战略布局与合作成果。线上渠道正成为体重管理的重要入口。与传统药品不同，体重管理类药物呈现出明显的消费医疗特性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101182013a48161cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101182013a48161cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","86618","LU2097828557.USD","LU0455707207.USD","LU2097828631.EUR","BK1247","SGXZ62798434.SGD","LU2097828474.EUR","01801","BK1142","LU0051755006.USD","LU2488822045.USD","BK1515","BK1574","LU0502904849.HKD","BK1161","LU1969619763.USD","SGXZ86797644.SGD","BK1615","LU2097828714.EUR","BK1571","BK1591","LU2097828805.USD","LU2242644610.SGD","06978","BK1583","06618","LU2328871848.SGD","LU0456827905.SGD"],"gpt_icon":0},{"id":"2580425750","title":"11月，新主线——极简投研","url":"https://stock-news.laohu8.com/highlight/detail?id=2580425750","media":"每经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580425750?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 18:20","pubTimestamp":1761992400,"startTime":"0","endTime":"0","summary":"被礼来压制的诺和诺德更是开价90亿美元，想抢辉瑞的收购标的Metsera。国内的减肥药公司，之前正是因为辉瑞收购Metsera，导致市场预期的BD梦想破灭，现如今又重新燃起了希望。有量有价有故事，创新药确实有成为11月主线的感觉。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101182118a6da3e6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101182118a6da3e6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046422090.SGD","LU0708995583.HKD","LU2242644610.SGD","06978","02359","06160","BK1574","BK1576","BK1141","LU0052750758.USD","LU2045819591.USD","LU2125910500.SGD","ONC","BK1161","LU0320764599.SGD","BK1583"],"gpt_icon":0},{"id":"2580441174","title":"中国人的药，治世界的病","url":"https://stock-news.laohu8.com/highlight/detail?id=2580441174","media":"正和岛","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580441174?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 11:30","pubTimestamp":1761967814,"startTime":"0","endTime":"0","summary":"一次符合国际标准的临床试验，成本动辄数亿美元，却是药企走向世界的必由之路。比如新冠疫情期间，国内主要用的还是布洛芬、对乙酰氨基酚等传统退烧药，真正有效的创新抗病毒药物非常少。中国的创新药，起点确实不高。数据显示，截至今年一季度，全球在研的PD-1药物中，有55%来自中国企业。中国企业基于国内生命科学和化学工程类人才优势，通过短周期分子设计与假设验证的迭代循环，在ADC等领域实现了局部“弯道超车”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101115147a480fed0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101115147a480fed0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01530","BK1574","LU1969619763.USD","LU2328871848.SGD","BK1161","ONC","09995","06978","BK1583","06160"],"gpt_icon":0},{"id":"2580410734","title":"速递丨10余款癌症管线正在临床推进，和誉医药展示创新管线布局与前沿临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2580410734","media":"医药观澜","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580410734?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 09:20","pubTimestamp":1761960030,"startTime":"0","endTime":"0","summary":"10月30日，和誉医药宣布2025研发日在上海成功举办，展示了公司最新创新管线布局与前沿临床进展。ABSK011在1期和2期临床研究中显示出40%至50%的有效率，今年5月份启动的注册性临床覆盖中国国50余家中心。口服小分子PD-L1抑制剂ABSK043在临床研究中展现出类抗体疗效和极佳的口服便利性，同时良好的安全性显示其具备克服多药联合治疗安全性风险的潜力。ABSK043联合其他药物用于晚期NSCLC和胃癌一线治疗的2期临床研究正在进行中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101093525a6d9b6ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101093525a6d9b6ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02256","BK1515","LU2488822045.USD","BK1574","BK1161","09939"],"gpt_icon":0},{"id":"2580441391","title":"新桥生物携25名全职员工闯关港交所，云顶新耀、康桥资本参股","url":"https://stock-news.laohu8.com/highlight/detail?id=2580441391","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580441391?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 09:00","pubTimestamp":1761958800,"startTime":"0","endTime":"0","summary":"瑞财经 刘治颖10月31日，新桥生物向港交所主板提交上市申请书，高盛和中信证券为联席保荐人。新桥生物已于2020年1月22日起在纳斯达克上市交易。若此次顺利完成港交所上市，新桥生物将实现“美股+港股”双重上市格局。截至最后实际可行日期，新桥生物拥有25名全职员工。新桥生物表示，公司主要通过招聘网站、猎头、内部推荐及招聘会等渠道招聘员工，2024年大量员工通过内部推荐加入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110109063394e83810&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110109063394e83810&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2580445494","title":"28家药企涉商业贿赂案！多起医药虚假宣传曝光，大联盟集采中选结果出炉，恒瑞、乐普大爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2580445494","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580445494?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 08:18","pubTimestamp":1761956330,"startTime":"0","endTime":"0","summary":"看点view本周，2025年国谈开启，第十一批国采272家企业的453个产品拟中选，医药反腐再掀风暴，多起医药虚假宣传典型案例曝光。截至目前，国家医保局共开展十一批国家组织药品集采，成功采购490种药品。大联盟集采中选结果出炉10月29日，广东省药品交易中心发布广东联盟常见病慢性病药品接续采购中选结果通知。根据相关规定，责令当事人停止违法行为，并处20万元罚款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101085310a480c74b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101085310a480c74b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","BK1515","BK1574","LU1023057109.AUD","09939","01276","LU0359201612.USD","BK1161","BK1191","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2580449389","title":"格隆汇港股回购榜 | 10月31日","url":"https://stock-news.laohu8.com/highlight/detail?id=2580449389","media":"格隆汇","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580449389?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 08:00","pubTimestamp":1761955200,"startTime":"0","endTime":"0","summary":"其中，回购金额最大的为顺丰控股，回购数量497.00万 ，回购金额2.00亿。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/11/01080053948417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02120","IE00B067MR52.USD","09959","09890","01497","LU0140636845.USD","02373","02039","LU0287142896.SGD","BK1160","02190","IE00B031J352.USD","02273","02319","02299","06826","BK1574","LU0048580855.USD","00732","00777","02869","06936","BK1201","08128","BK1103","LU0163747925.USD","LU0251143458.SGD","01583","02416","LU0228367735.SGD","06098","00909","06186","00418","01800","01919","01672","01681","06868","LU0370786039.SGD","LU0029875118.USD","01866","LU0315179316.USD","00103","00300","00386","01586","01373","02598","00947"],"gpt_icon":0},{"id":"2580445490","title":"中国首个，获批上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2580445490","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580445490?lang=zh_cn&edition=fundamental","pubTime":"2025-11-01 06:22","pubTimestamp":1761949331,"startTime":"0","endTime":"0","summary":"瑞乐唐是国内首个获批的此类产品，填补了国内市场空白。随着该药获批，公司已上市糖尿病新药增至5款，初步构建起覆盖糖尿病全病程的研发与产品矩阵。2025年1月，INS068的上市申请已获国家药监局受理。在持续高强度的研发驱动下，恒瑞创新成果爆发：2025年三季度财报显示，恒瑞已在中国获批上市24款1类创新药、5款2类新药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101064731a4809e6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251101064731a4809e6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","06978","LU0359202008.SGD","LU1023057109.AUD","BK1161","BK1574","01276","BK1191","LU0359201885.HKD","LU0359201612.USD"],"gpt_icon":0},{"id":"2580490245","title":"直击国谈第二日：肿瘤、慢病领域重磅药开谈！","url":"https://stock-news.laohu8.com/highlight/detail?id=2580490245","media":"猛犸资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580490245?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 22:09","pubTimestamp":1761919791,"startTime":"0","endTime":"0","summary":"10月31日是2025年国家医保谈判的第2日，各大医药企业代表在早上8点前就已排队进入全国人大会议中心。时代周报记者从全国人大会议中心西门现场了解到，第二天谈判主要涉及肿瘤、慢病等重大疾病领域，谈判节奏明显慢于前一天。时代周报记者从场外等候药企代表的交谈中得知，今天谈判药品包括抗肿瘤和慢病类药物，参与谈判多为肿瘤企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031230619a6d928b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031230619a6d928b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","06978","BK1161","02616","02575","BK1574","LU2543165471.USD","01276"],"gpt_icon":0},{"id":"2579454467","title":"腾盛博药-B(02137)授出60万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2579454467","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579454467?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 21:29","pubTimestamp":1761917376,"startTime":"0","endTime":"0","summary":"智通财经APP讯，腾盛博药-B(02137)发布公告，于2025年10月31日，公司根据2023年购股权计划条款向受让人授出60万份购股权，但须待受让人接纳。于本公告日期，已发行股份总数为7.209亿股(不包括库存股)。根据授出购股权授出的该等购股权获悉数行使后，据此将配发及发行的股份占本公告日期已发行股份总数(不包括库存股)约0.08%及经扩大已发行股份总数约0.08%(不包括库存股)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"腾盛博药-B(02137)授出60万份购股权","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02137","BK1587","BK1161"],"gpt_icon":0},{"id":"2579667467","title":"新股消息 | 礼邦医药递表港交所 核心产品AP301已完成中国III期注册临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2579667467","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579667467?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 21:08","pubTimestamp":1761916113,"startTime":"0","endTime":"0","summary":"礼邦医药从高磷血症领域切入，如今已拓展至整个肾脏病领域。公司的核心产品AP301是一款潜在BIC的磷酸盐结合剂，用于治疗高磷血症。AP301已完成中国III期注册临床试验，预计于近期提交新药申请，目前正在美国和中国开展全球III期关键多中心临床试验。另外，AP306是一款用于治疗高磷血症的潜在FIC泛磷酸盐转运蛋白抑制剂，已获得中国国家药监局的突破性疗法认定。礼邦医药目前正在探索全球商业及开发合作机会，以最大化AP301及AP306的全球市场价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","BK1574","09939","III","BK4134","HEXmain","BK1161"],"gpt_icon":0},{"id":"2579464507","title":"智通港股解盘 | 月底魔咒再起恒指跌破关口 医药目录谈判引发资金涌入","url":"https://stock-news.laohu8.com/highlight/detail?id=2579464507","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579464507?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 20:40","pubTimestamp":1761914421,"startTime":"0","endTime":"0","summary":"恒指收盘跌1.43%，破了26000点关口。周四美股三大指数均出现调整，Meta因其巨额AI支出计划而股价暴跌11%，引发了市场对AI投入产出比的广泛担忧。美国推行关税引发国内的不满，美参议院通过终止特朗普全面关税政策决议，但这些决议接下来还须经众议院表决。今日，2025年国家医保目录现场谈判与商保创新药目录价格协商在北京全国人大会议中心继续推进。今年国谈在延续医保目录常规调整机制的基础上，首次正式引入“商保创新药目录”机制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1046422090.SGD","SG9999014674.SGD","03877","02833","159938","02343","01919","BK1103","09939","MCHmain","LU0390135332.USD","BK4614","HHImain","BK1505","BK1535","LU0049112450.USD","01138","LU0390135506.SGD","SG9999011746.SGD","BK1166","SG9999003461.SGD","BK1515","513600","SG9999001440.SGD","LU0390135688.USD","LU0300738605.USD","BK1186","SG9999001093.SGD","HSI","LU0300738514.USD","SG9999002950.SGD","YANG","BK1161","HSImain","MHImain","LU1235295612.USD","BK1574"],"gpt_icon":0},{"id":"2579462460","title":"ETF日报：各方面利好消息不断出现，为行业乐观情绪再添一把火，关注创新药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2579462460","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579462460?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 20:39","pubTimestamp":1761914340,"startTime":"0","endTime":"0","summary":"受隔夜美股科技股表现疲弱等利空因素影响，A股今日小幅低开后震荡下行，前期表现强势的海外映射板块领跌两市。两市涨多跌少，共计3759家上涨，1548家下跌。成交方面，沪深两市成交额约2.35万亿，较昨日缩量超千亿，但仍较上周水平有所放大，市场热度逐渐恢复。　　板块方面，沉寂多日的创新药、软件、传媒等板块领涨。　　产业消息方面，利好消息不断出现，为行业乐观情绪再添一把火。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-31/doc-infvuxsn3202541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK4585","BK4588","BK1574","06978","BK4550","FDN","BK1161"],"gpt_icon":0},{"id":"2579469924","title":"创新药突然爆发，基金经理火线解读！多头猛攻，港股通创新药ETF（520880）大阳线拔地而起，放量摸高5.25%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2579469924","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579469924?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 19:53","pubTimestamp":1761911580,"startTime":"0","endTime":"0","summary":"10月最后一个交易日，沉寂已久的创新药板块突然大爆发，A港同频共振。重仓A股创新药的药ETF场内劲涨2.46%，三生国健20CM涨停。港股创新药尽显高弹性，100%创新药研发标的——港股通创新药ETF放量上探5.25%！业内人士指出，此举有望分流缓解高值创新药的支付压力。　　技术面看港股通创新药ETF，亮点颇多。　　港股通创新药ETF基金经理丰晨成最新表示，创新药行情可能随时再次启动，当下或是中长期维度配置创新药的高胜率区间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-10-31/doc-infvuxsi8523212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1161","06978","BK1574","520880"],"gpt_icon":0},{"id":"2579463926","title":"归创通桥(02190)10月31日耗资约118.74万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2579463926","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579463926?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 19:14","pubTimestamp":1761909296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)公布，2025年10月31日耗资约118.74万港元回购5万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02190","BK1587","BK1100","BK1574","BK1583"],"gpt_icon":0},{"id":"2579633134","title":"迈博药业-B(02181)：张雁云已获指定为首席独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2579633134","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579633134?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 19:07","pubTimestamp":1761908823,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈博药业-B(02181)发布公告，自2025年10月31日起：执行董事钱卫珠博士已获委任为本公司提名委员会成员;执行董事陶静先生已不再担任提名委员会成员;及张雁云博士(本公司独立非执行董事(独董)、本公司薪酬委员会主席及提名委员会成员)已获指定为首席独立非执行董事(首席独董)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02181","BK1574"],"gpt_icon":0},{"id":"2579468627","title":"歌礼制药-B(01672)10月31日耗资约193.27万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2579468627","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579468627?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 18:56","pubTimestamp":1761908168,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，2025年10月31日耗资约193.27万港元回购20万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01672","BK1574","01477","BK1161","BK1191"],"gpt_icon":0},{"id":"2580249194","title":"9个月干了过去3年IPO总和，这个领域何以爆发？","url":"https://stock-news.laohu8.com/highlight/detail?id=2580249194","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580249194?lang=zh_cn&edition=fundamental","pubTime":"2025-10-31 18:41","pubTimestamp":1761907267,"startTime":"0","endTime":"0","summary":"港股医疗保健行业通过IPO募资金额超过过去3年全年总和。仅9月以来，就有超12家药企向港交所递交IPO申请。截至2025年10月23日，港交所正在处理的上市申请约300家，其中半数为新经济领域企业，涵盖人工智能、生物技术等行业。这是2025年前十个月，中国创新药的大致表现。仅今年上半年，国家药品监督管理局批准创新药达40种，接近2024年全年总量。因为早期投入的企业得到了非常好的回报，这时中国创新药投融资开始爆发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103118432394e75504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103118432394e75504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","BK1588","LU1969619763.USD","BK1583","LU0307460666.USD","LU0588546209.SGD","06978","BK1574","LU1303224171.USD","LU1719994722.HKD","LU1770034418.SGD","LU2328871848.SGD","LU1251922891.USD","BK1161","BK1500"],"gpt_icon":0}],"pageSize":20,"totalPage":30,"pageCount":1,"totalSize":584,"code":"91000000","status":"200"}]}}